Q1 Earnings Estimate for NRIX Issued By Leerink Partnrs

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Nurix Therapeutics in a research note issued to investors on Monday, March 17th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($0.89) for the quarter. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics' Q2 2025 earnings at ($0.93) EPS.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%.

Several other research analysts have also issued reports on the stock. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research report on Friday, December 6th. They issued an "outperform" rating and a $35.00 price target on the stock. HC Wainwright lifted their price target on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. BTIG Research initiated coverage on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $35.00 price target on the stock. Royal Bank of Canada lifted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. Finally, Morgan Stanley lifted their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Nurix Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $30.88.

Remove Ads

Nurix Therapeutics Stock Performance

Shares of NRIX stock traded down $0.88 during mid-day trading on Wednesday, hitting $12.99. 2,288,289 shares of the stock traded hands, compared to its average volume of 870,393. The firm has a market cap of $985.77 million, a price-to-earnings ratio of -4.49 and a beta of 2.18. Nurix Therapeutics has a twelve month low of $11.90 and a twelve month high of $29.56. The company's 50-day simple moving average is $17.00 and its 200-day simple moving average is $20.77.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Houte Hans Van sold 5,825 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company's stock, valued at $488,660.76. This represents a 14.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,326 shares of company stock worth $213,449 over the last 90 days. 7.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nurix Therapeutics

A number of large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in Nurix Therapeutics in the fourth quarter worth $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Nurix Therapeutics by 14.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 146,713 shares of the company's stock worth $2,764,000 after purchasing an additional 18,189 shares in the last quarter. Woodline Partners LP boosted its holdings in Nurix Therapeutics by 0.5% in the fourth quarter. Woodline Partners LP now owns 338,462 shares of the company's stock worth $6,377,000 after purchasing an additional 1,583 shares in the last quarter. Velan Capital Investment Management LP acquired a new position in Nurix Therapeutics in the 4th quarter valued at $1,844,000. Finally, Vestal Point Capital LP grew its stake in Nurix Therapeutics by 14.1% in the 4th quarter. Vestal Point Capital LP now owns 485,000 shares of the company's stock valued at $9,137,000 after buying an additional 60,000 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.